Hydroxyurea: An Option for Preventing Sickle Cell Stroke
A drug that eases some of the painful symptoms of sickle cell anemia in children might also help prevent one of the worst symptoms, stroke.
As reported in MedPage Today and other news outlets, a two-year clinical trial led in part by Cincinnati Children’s showed that the oral medication hydroxyurea was as good as standard therapy (monthly transfusions) in preventing stroke risk for children with sickle cell. Russell Ware, MD, PhD, one of the study’s principal investigators and director of the Division of Hematology at Cincinnati Children’s, presented the findings on Dec. 6 at the American Society of Hematology meeting in Orlando. Data from the clinical trial also were published that same day by The Lancet.
Read more about the study in MedPage Today.